Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Multiple Myeloma 2Cytokine Release Syndrome 2Thrombocytosis 1Thrombocytopenia 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Lymphoma, Follicular 1Lymphoma 1Castleman Disease 1Burkitt Lymphoma 1Anemia 1

Interventions

tocilizumab 1temsirolimus 1siltuximab 1Zidovudine 1Valproic Acid 1Valganciclovir 1Sirolimus 1Rituximab 1Nelfinavir 1Immunoglobulin G 1Genetic Testing 1Disulfides 1Diagnostic Tests, Routine 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castleman Disease × siltuximab × Lymphoid × Clear all
NCT00412321 2014-07-01

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Centocor, Inc.

Phase 1 Completed
67 enrolled
LymphoidPlasma cell

Castleman Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡